ARA-290 is a peptide bioregulator with pronounced anti-inflammatory and neuroprotective effects, developed on the basis of an erythropoietin fragment without its hematopoietic effects. It works with pain, inflammatory, and sensorineural mechanisms without affecting hemoglobin levels. The peptide reduces neuroinflammation, supports the repair of nerve fibers and improves microcirculation. ARA-290 is particularly interesting in the context of neuropathic pain, chronic inflammatory conditions, and damage related to the nervous system and endothelium. It is integrated into programs of neuroprotection, vascular health support and a systemic antiage approach, where the accuracy of exposure and good tolerance of ARA-290, a peptide for fine work with pain, inflammation and restoration of nervous regulation without gross intervention, are important.
General information
| Features | Values |
|---|---|
| The peptide sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| The molecular formula | C51H84N16O21 |
| Molecular weight | 1257.3 g/mol |
| CAS Number | 1208243-50-8 |
| PubChem CID | 91810664 |
| Synonyms | ARA-290, ARA290, Cibinetide, PH-BSP, pHBSP peptide |
Lyophilized peptides
All peptides undergo lyophilization, a process that is necessary to extend their shelf life, as well as preserve the purity and integrity of the peptides during storage and transportation. Product Usage: This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
Product Usage
This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
The purity of peptides is more than 99%
Confirmed by certified laboratories. The analysis certificates are available before purchase.
GMR Production Standards
Manufactured in enterprises in accordance with good manufacturing practices. Complete documentation on tracking the origin of the product.
Execution of orders at the highest level
Sending orders the next day at checkout before 12:00 Moscow time. Free standard shipping across the country for orders starting from 15,000₽ (or equivalent).
Without fillers and additives
Only pure active connections. The composition is confirmed by experts for reliable in vitro studies.
ARA-290 is a synthetic peptide, also known as cibinetide, created on the basis of a spatial region of erythropoietin, but without its erythropoietic activity. The main interest in it is not related to the stimulation of erythropoiesis, but to the activation of the so-called innate repair receptor, which is associated with cytoprotection, anti-inflammatory response and tissue repair. That is why ARA-290 is considered as a research molecule for neuropathy, tissue damage, metabolic disorders, and ischemic-inflammatory conditions. ARA 290, a non-erythropoietic peptide developed based on erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes mellitus (PMC)
Neuropathic pain and low-fiber neuropathy
The main research area of ARA-290 is related to low-fiber neuropathy and neuropathic pain. In clinical studies in patients with sarcoidosis, ARA-290 treatment was accompanied by a decrease in neuropathic symptoms, and more recent publications also reported signs of regeneration of small nerve fibers, including improvement by corneal confocal microscopy. It was this data line that made ARA-290 one of the most notable molecules in the small fiber neuropathy research field. Safety and efficacy of ARA 290 in patients with sarcoidosis and symptoms of small fiber neuropathy: a randomized, double—blind pilot study - PMC
Metabolic disorders and diabetic neuropathy
ARA-290 has also been studied in patients with type 2 diabetes mellitus, where improvements in neuropathic symptoms and selected metabolic parameters have been reported. In the work of Brines et al. The authors explicitly noted that ARA-290 can be useful for both neuropathy and metabolic control, and modern reviews continue to consider it as an interesting molecule at the junction of inflammation, insulin resistance, and peripheral nerve damage. At the same time, this area is still a research area, not a standard of therapy. ARA 290, a non-erythropoietic peptide developed based on erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes mellitus (PMC)
Anti-inflammatory and cytoprotective effects
Mechanistically, ARA-290 is particularly interesting because it is associated with the suppression of inflammatory cascades and the launch of tissue repair programs. Modern experimental studies describe its effect on NLRP3-inflammasome, microglia, and inflammatory response after nerve injury, and earlier clinical and review publications associate its effect with anti-inflammatory and tissue-protective signaling through the innate repair receptor. This makes ARA-290 an important research molecule not only for pain, but also for broader models of chronic inflammation and tissue damage. ARA290, an alternative to erythropoietin, suppresses NLRP3 inflammasome activation in Schwann cells after sciatic nerve injury -- ScienceDirect
Ischemia, kidneys, and organoprotection
A separate area of research is related to ischemic reperfusion injury. In preclinical work on renal ischemia, ARA-290 improved functional parameters and reduced structural damage to the kidneys after reperfusion. Against this background, the molecule began to be considered as a potential cytoprotective peptide for conditions where tissue damage is triggered by ischemia, inflammation, and secondary oxidative stress. But here we are talking mainly about the preclinical base. ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury — PubMed
Neuroprotection and the central nervous system
ARA-290 is also being studied neuroprotectively. More recent experimental studies have reported that it reduced brain damage during ischemia and attenuated depression-like behavior in stress models, probably partly through anti-inflammatory mechanisms. These data look promising, but for the website it is better to present them as preclinical research directions, rather than as an already formed clinical application. A peptide derived from erythropoietin ARA290 mediates the protection of brain tissue through a β-pervasive receptor in mice with cerebral ischemic stroke - Wang - 2024 - Neuroscience and CNS Therapy - Wiley Online Library
Links
